Klin Farmakol Farm. 2023;37(2):49-51 | DOI: 10.36290/far.2023.008

Nejvýznamnější enzymy druhé fáze metabolismu léčiv: UDP-glukuronosyltransferázy a sulfotransferázy

Pavel Anzenbacher
Ústav farmakologie LF UP a FN Olomouc

Accepted: July 10, 2023; Published: July 10, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Anzenbacher P. Nejvýznamnější enzymy druhé fáze metabolismu léčiv: UDP-glukuronosyltransferázy a sulfotransferázy. Klin Farmakol Farm. 2023;37(2):49-51. doi: 10.36290/far.2023.008.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Anzenbacher P, Chládek J. Farmakokinetika. In: Švihovec J, Bultas J, Anzenbacher P, Chládek J, Příborský J, Slíva J, Votava M, editoři. Farmakologie. Praha: Grada. 2018; 35-96.
    2. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimete the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet. 1997;32(3):210-268. Go to original source... Go to PubMed...
    3. Guengerich FP. Inhibition of cytochrome P450 enzymes by drugs - Molecular basis and practical applications. Biomol Ther (Seoul). 2022;30(1):1-18. doi: 10.4062/biomolther.2021.102. Go to original source... Go to PubMed...
    4. Abraham S, Nohria A, Neilan TG, et al. Cardiovascular drug interactions with nirmatrelvir/ritonavir in patients with COVID-19. J Am Coll Cardiol. 2022;80(20):1912-1924. Go to original source... Go to PubMed...
    5. Meech R, Hu DG, McKinnon RA, et al. The UDP-glycosyltransferase (UGT) superfamily: New members, new functions, and novel paradigms. Physiol Rev. 2019;99:1153-1222. Go to original source... Go to PubMed...
    6. Stingl JC, Bartels H, Viviani R, et al. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review. Pharmacol Tharap. 2014;141:92-116. Go to original source... Go to PubMed...
    7. Petrenaite V, Öhmann I, Jantzen FPT, et al. Effect of UGT1A4, UGT2B7, UGT2B15, UGT2B17 and ABC1B polymorphisms on lamotrigine metabolism in Danish patients. Epilepsy Res. 2022;182:106897. Go to original source... Go to PubMed...
    8. Landerer S, Kalthoff S, Strassburg CP. UDP-glucuronosyltransferases mediate coffee-associated reduction of liver fibrosis in bile duct ligated humanized transgenic UGT1A mice. Hepatobilliary Surg Nutr. 2021;10(6):766-781. Go to original source... Go to PubMed...
    9. Kurogi K, Rasool M, Alherz FA, et al. Sult genetic polymorphisms: physiological, pharmacological and clinical applications. Expert Opinion Drug Metab Toxicol. 2021;20(21):767-784. Go to original source... Go to PubMed...
    10. Clayton TA, Baker D, Lindon JC, et al. Pharmacometabonomic identicication of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci US. 2009;106(34):14728-14733. Go to original source... Go to PubMed...
    11. Isvoran A, Peng Y, Ceauranu S, et al. Pharmacogenetics of human sulfotransferases and impact of amino acid exchange on Phase II drug metabolism. Drug Discovery Today. 2022;27(11):1-13. Go to original source... Go to PubMed...
    12. Allain EP, Rouleau M, Lévesque E, et al. Emerging roles for UDP-glucuronosyltransferases in drug resistence and cancer progression. Br J Cancer. 2020;122:1277-1287. Go to original source... Go to PubMed...
    13. Chodounský K. Farmakologie. Praha: Bursík a Kohout. 1905;30.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.